Navigation Links
Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
Date:6/11/2008

ut Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the expected completion of the acquisition of Parkway by Rosetta and the expected impact the acquisition, if completed, will have on the commercialization of Rosetta's microRNA-based diagnostics, Parkway's expected revenues and operating income for 2008, the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. /C O R R E C T I O N -- Rosetta Genomics Ltd/
2. Rosetta Genomics Reports First Quarter 2008 Financial Results
3. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
4. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
5. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
6. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
7. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
8. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
9. Rosetta Genomics Establishes Medical Advisory Board
10. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
11. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 2Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 3Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 4Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 5Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 6Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 7Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 8Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 9Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 10Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 11Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 12Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 13Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 14Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 15Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 16Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements 2Genta Incorporated to Present at the BIO CEO & Investor Conference 2Genta Incorporated to Present at the BIO CEO & Investor Conference 3
Breaking Biology News(10 mins):ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 2Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 1U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 2U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 3U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 4Hormone ghrelin can boost resistance to Parkinsons disease 10903 1Hormone ghrelin can boost resistance to Parkinsons disease 10903 2Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 1Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 2Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 3Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 4Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 5